chemagic 360
The chemagic™ chemagic 360 instrument is a flexible compact solution for automated nucleic extraction from diverse sample materials.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
gives you time for a tea
DNA extraction
Requires a fair bit of prep depending on the sample type.... but I'm sure that is the same for any automated extraction. Engineers come when needed, for the odd breakdown and service. Takes about 70 mins but reduces hands on time, letting you do something whilst samples are being extracted. Not as fast as some methods but still a helpful tool in the lab. Easy to use. Not exactly cheap to run though, but good for large runs.
Review Date: 12 May 2023 | Revvity
The chemagic 360 instrument is based on the well-established magnetic bead based chemagic Technology and the system offers a reliable solution for different sample materials and throughput needs. Configurable with three kinds of chemagic Rod Heads, the system can process sample volumes from 50 µl - 18 ml and the isolated DNA/RNA is suitable for a wide range of downstream applications such as NGS, MPLA, genotypic, and PCR.
Driving precision oncology with chemagic technology
Despite its great value as a biomarker, extracting and purifying circulating free DNA (cfDNA) has traditionally posed challenges due to its low concentration and high level of fragmentation within the bloodstream. Revvity’s chemagic™ technology promises to offer a robust solution to address these challenges. Leveraging M-PVA magnetic bead technology to extract cfDNA from large plasma volumes, the DNA extraction and purification platform is designed to maximize yield and purity. When combined with advanced quantification technology such as Droplet Digital™ PCR (ddPCR), the workflow provides precision and repeatability in early cancer biomarker research.
In this case study, Revvity explores how chemagic DNA extraction and purification technology is helping to optimize results.
Whole genome sequencing is driving improved health outcomes for newborns
Millions of people (many of them infants and young children) suffer from misdiagnosed or undiagnosed diseases due to insufficient genetic testing. Whole genome sequencing (WGS) has the potential to streamline genetic assessments and help provide early intervention.
In this case study, Revvity assesses the clinical utility of genome sequencing versus a gene panel for a curated set of medically actionable pediatric-onset conditions in the largest-to-date cohort of apparently healthy newborns and children tested at a single clinical laboratory.
Revvity broadens relationship with Genomics England to advance genomics in the UK
Collaboration to advance newborn genetic screening, leveraging cutting-edge genomics research and laboratory expertise to detect rare conditions early
